Key points
- Millennium runs 340+ investment teams, Point72 200+, all trading separately under one firm name.
- Teams work under hard loss limits. At Millennium, 5% down cuts a team's risk in half and 7.5% ends it.
- Citadel's latest quarterly holdings report listed 15,589 positions. Berkshire Hathaway's listed 90.
- A 13F or 13G from one of these firms is one team's position, not a house view.
Millennium Management disclosed on July 20 that it had crossed 5 percent of Perspective Therapeutics (CATX). Two days later it turned up owning 5.2 percent of Ameresco (AMRC), 1.8 million shares, the same week that stock closed at its cheapest level of 2026. Point72 had disclosed 5.3 percent of Evommune (EVMN) four days before the first of those.
Every time I wrote one of those up, I stopped and spent a sentence or two explaining that the stake belongs to one team inside the firm and not to the firm itself. Three times in ten days. Here's the version I should have written first.
What a pod shop actually is
Millennium's website puts the count at 340+ investment teams, next to 6,800 employees and more than $92 billion. Point72's own page says 200+ investing teams and about $58.5 billion, as of July 1. The industry nickname for this arrangement is a pod shop. The polite version is multi-manager.
A pod is small. One portfolio manager, an analyst or two, sometimes a trader of its own. Marc Rubinstein, a former analyst who writes the Net Interest newsletter, describes the setup plainly: capital is allocated from the centre as are the teams' risk parameters. So the team gets money and it gets a lane. What it does inside that lane is its own business, and it keeps a cut. He puts the standard deal at 15-20% of the profits they generate in addition to having expenses paid for.
Israel Englander founded Millennium in 1989, and his name sits on the Ameresco filing alongside Millennium Management LLC and Millennium Group Management. He didn't pick Ameresco.
The firm can take the capital back
Rubinstein on what happens to a team that goes wrong: At Millennium, a 5% drawdown leads to the team having their risk cut in half; a 7.5% drawdown leads to a complete wind-down of the portfolio.
That isn't a guideline somebody reviews at the end of the quarter. It's automatic, and it churns through people at a rate that would count as a crisis in most businesses. Rubinstein again: portfolio manager turnover can be 15-20% per year. Which means whoever bought Perspective Therapeutics back in June might not be there now, and nothing in the July filing would give it away.
Who pays for the machinery
Most of these firms dropped the traditional management fee years ago and bill investors for the cost of running the place instead. Compensation is the big one, but it covers everything down to the rent. The performance fee comes after that. BNP Paribas put a number on where it lands: investors in multi-strategy funds kept 41 cents of every dollar the funds earned in 2023, down from 54 cents two years before.
What investors are buying is a return that doesn't rise and fall with the market. Business Insider's mid-year scorecard put Point72 up 14.5 percent through the first half of 2026, Millennium up 10.5 percent and Citadel's Wellington fund up 5.7 percent. That steadiness is the product, and it's why a pod that stops earning gets cut so quickly.
What the cover pages show
Anyone managing more than $100 million in US stocks has to file a quarterly holdings report, a 13F, within 45 days of the quarter closing. The March quarter came due on May 15. I pulled the cover pages.
| Firm | Positions listed | Reported value |
|---|---|---|
| Citadel Advisors | 15,589 | $618 billion |
| Millennium Management | 5,624 | $240 billion |
| Point72 Asset Management | 3,704 | $78 billion |
| Berkshire Hathaway | 90 | $263 billion |
| Pershing Square Capital | 11 | $13.7 billion |
Bill Ackman's Pershing Square listed eleven. Citadel filed 15,589 lines, and I'd bet nobody there has read the whole thing end to end. Berkshire's 90 lines arrive across fifteen separate insurance and holding entities that file as a group.
Inside one row of a 13F
Each row of a 13F table carries a company name, a CUSIP, a dollar value, a share count, and one small box marked put or call. That's the entire row.
That last box does heavy lifting at these firms. Of Citadel's 15,589 lines, 7,304 are options rather than stock, and 3,419 of those are puts. Point72's table runs 1,721 options inside its 3,704 lines. Positions that pay off when a stock falls turn up on these filings constantly.
The one thing the table omits entirely is stock sold short. That omission does its real damage at a pod shop, where a team will buy one company while betting against a rival in the same business, so Ameresco appears on Millennium's filing and a short position sitting against it wouldn't.
The filing that carries a date
Millennium filed twice on Perspective Therapeutics inside three weeks. The June 30 filing reported 4.3 percent of the company as of June 23. The July 20 filing reported 5.3 percent as of July 13. Between those two dates the fund bought about a million more shares and crossed the line where the law requires an owner to raise a hand in public.
Event dates are why I'll read a 13G closely, because they put a window around the buying. The cover page names the same three parties every time: Millennium Management LLC, its parent Millennium Group Management, and Englander. All three are legal entities and a founder. The team that actually made the call stays anonymous. If the 13D and 13G distinction is new to you, my piece on the difference covers it.
So what is it good for
Nobody has to say anything until a stake reaches 5 percent of a company. Millennium's Ameresco position is $42.5 million inside a company worth about $800 million on the day the filing landed, which puts it at 5.2 percent.
Point72's Evommune filing is the one I keep going back to. Evommune had already fallen about 40 percent on a failed drug trial by the time the fund showed up. The stock closed at $12.45 the day the stake crossed 5 percent. It closed at $11.36 on July 24.
The cover page leaves purchase price blank. Point72 could be well ahead on Evommune or deeply underwater, and the filing doesn't say which. The team behind the trade isn't named either, and neither is the day they started buying.
I keep reading them anyway.
For the longer answer to the "should I just copy them" question, our piece on whether copying hedge funds, Congress and insiders actually works goes through the research. Our hedge fund tracker pulls these filings the day they land, and any company's filings page has the raw documents.
Sources
- Millennium Management, firm figures, and Point72, firm figures as of July 1, 2026
- SEC EDGAR, Q1 2026 Form 13F-HR cover pages: Citadel Advisors, Millennium Management, Point72, Berkshire Hathaway, Pershing Square
- Marc Rubinstein, Net Interest, Peak Pod (quoted on capital allocation, risk limits, turnover and pod economics)
- Business Insider, multi-strategy performance scorecard, first half 2026
- Our coverage of the filings referenced above: Millennium and Perspective Therapeutics (CATX), Millennium and Ameresco (AMRC), Point72 and Evommune (EVMN)
This is general market commentary and opinion, not investment advice. Always do your own research and consider speaking with a licensed financial professional before making any investment decision.
